Literature DB >> 25343275

Conditional deletion of Men1 in the pancreatic β-cell leads to glucagon-expressing tumor development.

Feng Li1, Yutong Su, Yulong Cheng, Xiuli Jiang, Ying Peng, Yanli Li, Jieli Lu, Yanyun Gu, Changxian Zhang, Yanan Cao, Weiqing Wang, Guang Ning.   

Abstract

The tumor suppressor menin is recognized as a key regulator of β-cell proliferation. To induce tumorigenesis within the pancreatic β-cells, floxed alleles of Men1 were selectively ablated using Cre-recombinase driven by the insulin promoter. Despite the β-cell specificity of the RipCre, glucagon-expressing tumors as well as insulinomas developed in old mutant mice. These glucagon-expressing tumor cells were menin deficient and expressed the mature α-cell-specific transcription factors Brain-specific homeobox POU domain protein 4 (Brn4) and v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (MafB). Moreover, the inactivation of β-cell-specific transcription factors was observed in mutant β-cells. Our work shows that Men1 ablation in the pancreatic β-cells leads to the inactivation of specific transcription factors, resulting in glucagon-expressing tumor development, which sheds light on the mechanisms of islet tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25343275     DOI: 10.1210/en.2014-1433

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Upregulated Pdx1 and MafA Contribute to β-Cell Function Improvement by Sleeve Gastrectomy.

Authors:  Feng Li; Han Cao; Chunjun Sheng; Hang Sun; Kexiu Song; Shen Qu
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

2.  Preventative Sleeve Gastrectomy Contributes to Maintaining β Cell Function in db/db Diabetic Mouse.

Authors:  Feng Li; Chunjun Sheng; Kexiu Song; Manna Zhang; Le Bu; Peng Yang; Hui Sheng; Hong Li; Shen Qu
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

Review 3.  Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Authors:  Koen M A Dreijerink; H T Marc Timmers; Myles Brown
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

4.  Reversibility of β-Cell-Specific Transcript Factors Expression by Long-Term Caloric Restriction in db/db Mouse.

Authors:  Chunjun Sheng; Feng Li; Ziwei Lin; Manna Zhang; Peng Yang; Le Bu; Hui Sheng; Hong Li; Shen Qu
Journal:  J Diabetes Res       Date:  2016-02-21       Impact factor: 4.011

5.  Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.

Authors:  Kathrin Fielitz; Kristina Althoff; Katleen De Preter; Julie Nonnekens; Jasmin Ohli; Sandra Elges; Wolfgang Hartmann; Günter Klöppel; Thomas Knösel; Marc Schulte; Ludger Klein-Hitpass; Daniela Beisser; Henning Reis; Annette Eyking; Elke Cario; Johannes H Schulte; Alexander Schramm; Ulrich Schüller
Journal:  Oncotarget       Date:  2016-11-15

6.  A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.

Authors:  K E Lines; R P Vas Nunes; M Frost; C J Yates; M Stevenson; R V Thakker
Journal:  Endocr Connect       Date:  2017-04-18       Impact factor: 3.335

Review 7.  Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Authors:  Gabriel Benyomo Mpilla; Philip Agop Philip; Bassel El-Rayes; Asfar Sohail Azmi
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

8.  ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.

Authors:  Chang S Chan; Saurabh V Laddha; Peter W Lewis; Matthew S Koletsky; Kenneth Robzyk; Edaise Da Silva; Paula J Torres; Brian R Untch; Janet Li; Promita Bose; Timothy A Chan; David S Klimstra; C David Allis; Laura H Tang
Journal:  Nat Commun       Date:  2018-10-12       Impact factor: 14.919

9.  Research progress of the transcription factor Brn4 (Review).

Authors:  Yuying Wu; Xunrui Zhang; Jue Wang; Guohua Jin; Xinhua Zhang
Journal:  Mol Med Rep       Date:  2021-01-05       Impact factor: 2.952

Review 10.  Current and emerging therapies for PNETs in patients with or without MEN1.

Authors:  Morten Frost; Kate E Lines; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-02-16       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.